Sporadic inclusion body myositis: Phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 79, Issue 9, 2008, Pages 1056-1060

  Needham, Merrilee ^a,g   James, I ^b   Corbett, A ^c   Day, T ^d   Christiansen, F ^e   Phillips, B ^f   Mastaglia, F L ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b MURDOCH UNIVERSITY   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e ROYAL PERTH HOSPITAL   (Australia)

^f LA TROBE UNIVERSITY   (Australia)

^g PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA DR3 ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISOLONE;

ADULT; AGED; ALLELE; ARTICLE; AUSTRALIA; CLINICAL EVALUATION; CLINICAL FEATURE; COHORT ANALYSIS; CORRELATION ANALYSIS; DIAGNOSTIC ERROR; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DISEASE PREDISPOSITION; DYSPHAGIA; FEMALE; FUNCTIONAL STATUS; GENETIC ASSOCIATION; GRIP STRENGTH; HLA DRB1 ALLELE; HLA TYPING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUSCLE BIOPSY; MUSCLE FATIGUE; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOSITIS; ONSET AGE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; SPORADIC INCLUSION BODY MYOSITIS; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIGENIC VARIATION; AUSTRALIA; AUTOANTIBODIES; CROSS-SECTIONAL STUDIES; DEGLUTITION DISORDERS; DEMOGRAPHY; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; HLA-DR3 ANTIGEN; HUMANS; MALE; MIDDLE AGED; MUSCLE FATIGUE; MUSCLE WEAKNESS; MYOSITIS, INCLUSION BODY; PHENOTYPE; PREVALENCE; QUADRICEPS MUSCLE;

EID: 50449098865     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2007.138891     Document Type: Article

References (28)

1. Felice KJ, North WA. Inclusion body myositis in Connecticut: Observations in 35 patients during an 8-year period. Medicine 2001;80:320-7.
2. Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve 2000;23:970-2.
3. O'Hanlon TP, Rider LG, Mamyrova G, et al. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: Allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum 2006;54:3670-81.
4. Shamim EA, Rider LG, Pandey JP, et al. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum 2002;46:1885-93.
5. Sordaroglu P, Deymeer F, Parman Y. Prevalence of Sporadic Inclusion Body Myositis (s-IBM) in Turkey: A muscle biopsy based survey. Neuromuscul Disord 2007;17:849.
6. Needham M, Mastaglia FL, Garlepp MJ. Genetics of inclusion-body myositis. Muscle Nerve 2007;35:549-61.
7. Hund E, Heckl R, Goebel HH. et al. Inclusion body myositis presenting with isolated erector spinae paresis. Neurology 1995;45:993-4.
8. Luque F, Rosenkilde C, Valsamis M. Inclusion body myositis presenting with dropped head syndrome. Brain Pathol 1994;4:568.
9. Schlesinger I, Soffer D, Lossos A. et al. Inclusion body myositis: atypical clinical presentations. Eur Neurol 1996;36:89-93.
10. McKee D, Karpati G, Carpenter S. et al. Familial inclusion body myositis mimics facioscapulohumeral dystrophy. Neurology 1992;42:302.
11. Badrising UA, Maat-Schieman MLC, van Houwelingen JC, et al. Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. J Neurol 2005;252:1448-54.
12. Felice KJ, Relva GM, Conway SR. Further observations on forearm flexor weakness in inclusion body myositis. Muscle Nerve 1998;21:659-61.
13. Phillips BA, Cala LA, Thickbroom GW, et al. Patterns of muscle involvement in sporadic inclusion body myositis. A clinical and MRI study. Muscle Nerve 2001;24:1526-34.
14. Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: Clinical and pathological boundaries. Ann Neurol 1996;40:581-6.
15. Beyenburg S, Zierz S, Jerusalem F. Inclusion body myositis: clinical and histopathological features of 36 patients. Clin Investig 1993;71:351-61.
16. Lindberg C, Persson LI, Bjorkander J, et al. Inclusion body myositis: clinical, morphological,physiological and laboratory findings in 18 cases. Acta Neurol Scand 1994;89:123-31.
17. Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol 1992;19:1385-9.
18. Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain 1989;112:727-47.
19. Ringel SP, Kenny CE, Neville HE, et al. Spectrum of inclusion body myositis. Arch Neurol 1987;44:1154-7.
20. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-13.
21. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007;6:620-31.
22. Brooke MH, Fenichel GM, Griggs RC, et al. Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve 1983;6:91-103.
23. Arnardottir S, Alexanderson H, Lundberg IE, et al. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med 2003;35:31-5.
24. Johnson LG, Edwards DJ, Walters S, et al. The effectiveness of an individualized, home-based functional exercise program for patients with sporadic inclusion body myositis. J Clin Neuromusc Disease 2007;8:187-94.
25. Spector SA, Lemmer JT, Koffman BM, et al. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve 1997;20:1242-8.
26. Needham M, Scott A, Laing N, et al. Disease modifying effects of MHC haplotypes in IBM. Neuromuscul Disord 2006;16 S86.
27. Mastaglia F, Price P, Walters S, et al. Familial inclusion body myositis in a mother and son with different ancestral MHC haplotypes. Neuromuscul Disord 2006;16:754-8.
28. Badrising UA, Schreuder GMT, Giphart MJ, et al. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 2004;63:2396-8.